Eyekandy Launches Brand ‘MetaStores’ for the Metaverse
19.1.2022 16:38:00 EET | Business Wire | Press release
Eyekandy, one of the world's leading Augmented Reality (AR) Providers for Commerce, today announced its MetaStore service for retailers and brands.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220118006141/en/
This is an example of a Metastore. #endlesspossibilities (Source: eyekandy Metastore)
The service will enable retailers and brands to easily deploy custom stores and sales campaigns into the metaverse to promote or sell digital goods, such as NFT’s. Metaverse projects can be a major cost and distraction for a marketing world that is still figuring out what the metaverse is and how it can be of most benefit. Eyekandy represents a one-stop-shop for retailers and brands to test and learn all things metaverse, without having to get into the detail of how to do it successfully.
Richard Clarke, Head of Metaverse & NFT’s at Eyekandy added: “Launching successfully in the Metaverse is a complex, multilayered project. It is a very new, cutting edge technology and sales and marketing channel - we are doing the learning and experimenting on behalf of our brand and retail partners, so they don't have to. There are multiple Metaverses and multiple ways to launch. 3D asset creation, NFT’s, purchasing digital real estate, community management, content moderation, combining digital and real-world merchandise and much more, needs careful consideration, planning and execution. Brands and retailers need our support. With our heritage in 3D and AR production and syndication, this is a very organic evolution of our business.”
“Eyekandy represents a one stop shop for retailers and brands who want to experiment in the Metaverse, without huge budgets or distraction.”
The Metaverse is a network of 3D virtual worlds focused on social connection. Since Facebook’s announcement to rebrand to META in October, it has attracted the global attention of brands. Nike, Samsung, Ralph Lauren and many more have all launched Metaverse projects to sell digital merchandise in the last three months alone.
Founder Scott Lester commented: “Our founding vision has always been to change the way the world shops with AR. This is now evolving to actually changing the world we shop in. Eyekandy has invested in digital real estate across the metaverse and our ‘metastore.x’ and ‘brandstore.x’ metaverse locations will enable our partners to engage and experiment quickly and easily with us in this new digital frontier. Brands need to be where the next generation of shoppers are – they are already in the Metaverse, shopping and buying.”
About Eyekandy
We’re changing the way the world shops with Augmented Reality. Based in London and Chicago, Eyekandy is the world's leading Augmented Reality (AR) Provider for Commerce. We partner with Retailers and Brands across the world to produce engaging AR shopper experiences in-store, online and in print. Our multi award winning, global AR shopping Platform, ‘Point & Place®’, is the world’s most adopted AR shopping platform, with hundreds of retailers connected across 30+ countries. Eyekandy has won numerous industry awards as we deliver innovation in creative ways to drive sales and engagement from shoppers with immersive ways to shop and browse.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220118006141/en/
Contact information
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom